IgA nephropathy, also called Berger disease, has moved from a “watch, wait, and hope the kidneys behave” condition to one of the most active areas in kidney medicine. For decades, treatment mostly meant controlling blood pressure, reducing protein in the urine, and using steroids carefully when the disease looked aggressive. That foundation still matters. In fact, it is the floor, the walls, and probably the plumbing of IgA nephropathy care. But the roof has changed dramatically.
Today, the treatment landscape of IgA nephropathy includes optimized supportive care, targeted-release corticosteroids, endothelin pathway drugs, complement inhibitors, and newer immune-targeted therapies that aim closer to the source of the disease. That is good news for patients, caregivers, and nephrologists who have spent years trying to slow a condition that can be quiet, stubborn, and occasionally as subtle as a fire alarm wrapped in a pillow.
This article explains where IgA nephropathy treatment stands now, how doctors think about risk, which therapies are changing care, and what real-world patient experience often looks like.
What Is IgA Nephropathy?
IgA nephropathy is a chronic kidney disease in which abnormal immune proteins, mainly immunoglobulin A, collect in the kidneys’ filtering units, called glomeruli. These deposits can trigger inflammation, blood in the urine, protein leakage, scarring, and gradual loss of kidney function.
Some people discover IgA nephropathy after seeing tea-colored or cola-colored urine following a respiratory infection. Others find out through routine testing that shows proteinuria, microscopic blood in the urine, or reduced estimated glomerular filtration rate, commonly called eGFR. A kidney biopsy is usually needed to confirm the diagnosis and understand the pattern of injury.
Why Treatment Is No Longer One-Size-Fits-All
IgA nephropathy can behave very differently from person to person. One patient may have mild urinary changes for decades. Another may lose kidney function steadily despite feeling perfectly fine. That unpredictability is why modern treatment focuses on risk stratification.
Key Risk Factors Doctors Watch
Doctors typically look at several markers before deciding how aggressive treatment should be:
- Proteinuria: Persistent protein in the urine is one of the strongest signs that the kidneys are under stress.
- eGFR trend: A falling eGFR suggests declining kidney function.
- Blood pressure: High blood pressure can worsen kidney damage and speed progression.
- Kidney biopsy findings: Scarring, inflammation, crescents, and tubular injury help predict risk.
- Hematuria: Ongoing blood in the urine may reflect active glomerular inflammation.
- Comorbidities: Diabetes, obesity, cardiovascular disease, liver disease, and infections may influence treatment choices.
The big idea is simple: treat the person, not just the lab number. IgA nephropathy may be one diagnosis, but it is not one identical disease story.
The Foundation: Optimized Supportive Care
Before discussing newer medications, it is important to give supportive care the respect it deserves. It may not sound glamorous, but it is the treatment layer that almost every patient needs.
Blood Pressure Control
Controlling blood pressure is central to IgA nephropathy treatment. When pressure inside the kidney filters stays too high, more protein leaks through, and scarring can accelerate. The goal is not just a nice-looking number at the clinic. The goal is to reduce stress on the kidney’s tiny filtration system every day.
ACE Inhibitors and ARBs
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are often first-line medications for people with IgA nephropathy and proteinuria. These drugs reduce pressure within the glomeruli, lower proteinuria, and help protect kidney function over time.
A practical example: a patient with a urine protein-to-creatinine ratio above target may start an ACE inhibitor or ARB, then have labs checked after dose adjustments. The doctor watches potassium, creatinine, blood pressure, and symptoms such as dizziness. The treatment is not “set it and forget it.” It is more like tuning a guitar: a little adjustment, listen carefully, adjust again.
SGLT2 Inhibitors
SGLT2 inhibitors were first known as diabetes medications, but kidney specialists now use them broadly in chronic kidney disease. In many patients, they can reduce proteinuria and slow loss of kidney function, including in people without diabetes. They are not IgA-nephropathy-specific, but they have become an important part of kidney-protective care.
Lifestyle Measures That Actually Matter
Lifestyle changes cannot “cure” IgA nephropathy, but they can make the kidney’s job easier. Common recommendations include reducing sodium, maintaining a healthy weight, exercising consistently, avoiding smoking, limiting excessive alcohol, and staying away from unnecessary nonsteroidal anti-inflammatory drugs such as ibuprofen or naproxen unless a clinician approves them.
Diet is individualized. Some patients need protein moderation, while others need attention to potassium, phosphorus, or fluid balance as kidney function changes. A kidney dietitian can be extremely helpful because “eat healthy” is not a plan; it is a bumper sticker.
Targeted-Release Budesonide: Treating the Gut-Kidney Connection
One of the biggest shifts in IgA nephropathy treatment is the recognition that the gut immune system plays an important role. Targeted-release budesonide is designed to act in the lower small intestine, where immune activity may contribute to production of abnormal IgA.
In the United States, delayed-release budesonide, marketed as Tarpeyo, is approved for adults with primary IgA nephropathy at risk for disease progression. Unlike traditional systemic steroids, this formulation aims to deliver corticosteroid activity more locally in the gut, reducingbut not eliminatingsystemic steroid exposure.
Where It Fits
Targeted-release budesonide may be considered for patients who remain at risk despite optimized supportive care. It is especially relevant when proteinuria remains elevated and the clinician believes immune activity is contributing to ongoing injury.
What Patients Should Know
Although targeted budesonide is not the same as high-dose systemic prednisone, it is still a corticosteroid therapy. Side effects can include swelling, acne, mood changes, blood pressure changes, or changes in blood sugar. The point is not to fear the medicine, but to monitor it intelligently.
Sparsentan: Dual Pathway Kidney Protection
Sparsentan, marketed as Filspari, represents another major development. It blocks both the endothelin type A receptor and the angiotensin II type 1 receptor. In plain English, it targets two pathways involved in kidney stress, blood vessel tone, inflammation, and protein leakage.
Sparsentan is approved in the United States to slow kidney function decline in adults with primary IgA nephropathy who are at risk for disease progression. Because it already blocks the angiotensin receptor pathway, it is not used together with ACE inhibitors or ARBs.
Why It Matters
For patients with persistent proteinuria, sparsentan offers a non-steroid option that directly targets protein leakage and kidney protection. It is particularly interesting because many patients and clinicians want effective treatment without jumping immediately to broad immunosuppression.
Safety Considerations
Sparsentan requires careful safety monitoring. It carries warnings related to liver toxicity and embryo-fetal toxicity, so liver tests and pregnancy precautions are part of treatment planning. It may also cause low blood pressure, swelling, anemia, or changes in kidney-related labs. This is a medicine that belongs in a serious care plan, not in a casual “let’s try this and see what happens” drawer.
Atrasentan: A Selective Endothelin A Receptor Option
Atrasentan, marketed as Vanrafia, is a selective endothelin A receptor antagonist approved under the accelerated approval pathway to reduce proteinuria in adults with primary IgA nephropathy at risk of rapid progression. It is taken orally and is not a steroid or broad immune suppressant.
The endothelin system can contribute to blood vessel constriction, inflammation, fibrosis, and proteinuria. By selectively targeting the endothelin A receptor, atrasentan aims to reduce kidney stress while avoiding some activity at endothelin B receptors.
Potential Role in Practice
Atrasentan may be considered in patients with significant proteinuria despite optimized background care. It adds another tool to the anti-proteinuria strategy, which is important because lowering proteinuria is one of the most practical ways clinicians track whether therapy is helping.
Monitoring Needs
Like other endothelin pathway therapies, atrasentan requires attention to pregnancy prevention, fluid retention, edema, blood pressure, and laboratory monitoring. Patients should also discuss all other medicines they take because drug interactions can matter.
Complement Inhibition: Fabhalta and the Immune Cascade
Complement activation is part of the immune injury seen in many patients with IgA nephropathy. Fabhalta, the brand name for iptacopan, is an oral factor B inhibitor that targets the alternative complement pathway. It has accelerated approval in the United States to reduce proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression.
This approach is exciting because it moves beyond simply reducing pressure inside the kidney filter. It targets an immune pathway that may help drive inflammation and damage.
Who Might Be Considered?
Complement inhibition may be discussed when a patient has persistent high-risk features, such as elevated proteinuria despite optimized care. The decision depends on the full clinical picture, including infection risk, vaccination history, other immune therapies, kidney function, and patient preference.
Important Safety Issues
Complement inhibitors can increase susceptibility to serious infections, especially infections caused by encapsulated bacteria. Vaccination planning and risk management are essential. This is not meant to scare patients away. It means the treatment should be handled with the same respect you would give a chainsaw: useful, powerful, and absolutely not something to wave around casually.
APRIL Blockade: A Newer Immune-Targeted Direction
Another major development is therapy aimed at APRIL, short for A Proliferation-Inducing Ligand. APRIL helps support B-cell activity and production of certain antibodies, including abnormal IgA involved in IgA nephropathy.
Sibeprenlimab, marketed as Voyxact, is an APRIL blocker approved under accelerated approval to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. It is given as a subcutaneous injection once every four weeks.
Why APRIL Is a Big Deal
APRIL blockade is important because it targets an upstream immune mechanism. Instead of only trying to protect the kidney after abnormal IgA has already arrived, this approach aims to reduce production of the problematic immune signals that contribute to disease activity.
Patient-Friendly but Still Serious
A once-monthly injection may be appealing for some patients compared with daily oral therapy. However, immune-targeted therapy still requires infection monitoring, vaccination discussions, and careful coordination with a nephrologist.
Systemic Corticosteroids: Still Useful, More Carefully Chosen
Traditional systemic corticosteroids, such as prednisone, have long been used in selected patients with IgA nephropathy. They can reduce inflammation, but they also come with familiar risks: infections, weight gain, mood changes, high blood sugar, bone thinning, sleep problems, acne, and the mysterious ability to make a refrigerator look like it is calling your name at 11:47 p.m.
Today, systemic steroids are generally used more selectively. Doctors weigh the potential kidney benefit against the patient’s infection risk, eGFR, age, diabetes status, obesity, liver disease, and other factors. The trend in modern IgA nephropathy care is not “more steroids for everyone.” It is “the right immune therapy for the right patient at the right time.”
Dialysis and Kidney Transplantation
Despite better treatments, some patients progress to kidney failure. At that point, dialysis or kidney transplantation may be needed. Transplantation can offer excellent outcomes for many patients, although IgA nephropathy can recur in the transplanted kidney. Recurrence does not always mean immediate kidney failure, but it does mean continued monitoring is necessary.
The hope is that earlier and more targeted treatment will reduce the number of people who reach this stage. That is the real promise of the modern treatment landscape: not just better lab numbers, but more years with functioning kidneys.
How Doctors Choose Among Treatments
With more options available, the question becomes: which therapy comes first? There is no single answer. A nephrologist may consider the following:
- How much protein is in the urine after supportive care is optimized
- How quickly eGFR is declining
- Whether blood pressure is controlled
- Biopsy findings and signs of active inflammation or chronic scarring
- Pregnancy plans or pregnancy risk
- History of infections or immune problems
- Medication access, insurance coverage, and patient preference
- Whether the patient prefers pills, injections, or time-limited therapy
For example, a younger adult with persistent proteinuria despite an ARB and SGLT2 inhibitor may be evaluated for an IgAN-specific therapy. A patient with high infection risk may not be the best candidate for certain immune-targeted approaches. A patient planning pregnancy needs a very different discussion from someone who is not. Treatment selection is now a chessboard, not a vending machine.
The Future of IgA Nephropathy Treatment
The future is moving toward combination strategies and precision medicine. Instead of asking whether one drug is “the IgA nephropathy drug,” clinicians increasingly ask which disease pathway is most active in a particular patient.
Several treatment categories are especially important for the future:
- B-cell and plasma-cell pathway therapies: These aim to reduce production of abnormal IgA.
- Complement inhibitors: These target immune activation inside the kidney.
- Endothelin receptor antagonists: These focus on proteinuria, inflammation, and kidney pressure dynamics.
- Gut-targeted therapies: These address immune activity linked to mucosal IgA production.
- Better biomarkers: These may help predict who needs aggressive therapy earlier.
The major challenge is sequencing. Should a patient start with kidney-protective therapy, then targeted immune therapy? Should therapies be combined? How long should treatment continue after proteinuria improves? These are the questions shaping the next decade of IgA nephropathy care.
Real-World Experiences in IgA Nephropathy Care
Living with IgA nephropathy is often less dramatic than people expect, but more emotionally demanding than outsiders realize. Many patients feel completely normal when their lab results say otherwise. That mismatch can be frustrating. It is hard to take a chronic disease seriously when you can still work, exercise, run errands, raise kids, travel, and argue with your Wi-Fi router like any healthy person.
A common experience begins with surprise. Someone goes in for a routine physical, a school exam, a military screening, or a checkup after seeing blood in the urine. Suddenly, words like proteinuria, creatinine, eGFR, biopsy, glomeruli, and nephrology enter the conversation. At first, the language can feel like someone spilled alphabet soup into a medical textbook. Patients often describe the first few months as a crash course in kidney biology they never requested.
Another shared experience is learning to track numbers without becoming controlled by them. Proteinuria may rise or fall. eGFR may fluctuate slightly from test to test. Blood pressure readings may look different at home than in the clinic. Patients often learn that one lab result is a snapshot, while the trend is the movie. A single scary number can ruin a weekend, but the larger pattern usually matters more. This is where a good nephrology team makes a huge difference. Clear explanations can turn panic into a plan.
Medication adjustment is also part of the journey. A patient may start an ARB and feel lightheaded for a week. Another may begin an SGLT2 inhibitor and need counseling about hydration and genital infection symptoms. Someone prescribed targeted-release budesonide may worry about steroid side effects. A person considering sparsentan, atrasentan, iptacopan, or sibeprenlimab may need to understand monitoring, pregnancy precautions, infection risks, vaccination requirements, and insurance paperwork. The medicine is only one part of treatment. The logistics are their own mini-marathon, preferably with snacks.
Diet changes can be surprisingly emotional. Reducing sodium sounds simple until a person realizes that restaurant food, canned soup, frozen meals, sauces, deli meats, and snack foods have been quietly throwing a salt party in the background. Patients often become label readers. Some get very good at cooking with herbs, citrus, garlic, vinegar, and spices. Others grieve the temporary loss of their favorite salty foods, which is fair. A kidney-friendly lifestyle should be practical, not joyless.
Many people with IgA nephropathy also describe a new relationship with uncertainty. The disease may remain stable for years, or it may require treatment escalation. That uncertainty can affect career planning, family planning, exercise routines, travel, finances, and mental health. Support groups, patient education organizations, counseling, and honest conversations with clinicians can help. Nobody should have to manage the emotional side of chronic kidney disease with nothing but internet searches and heroic pretending.
The most encouraging experience patients often report is gaining a sense of control. They may not control the diagnosis, but they can control appointments, blood pressure logs, medication adherence, sodium intake, exercise habits, sleep, follow-up labs, and asking better questions. Modern IgA nephropathy care is increasingly collaborative. Patients are not passive passengers in the back seat. They are part of the navigation team, ideally with a nephrologist who knows the route and does not mind explaining the map.
Conclusion
The treatment landscape of IgA nephropathy has changed rapidly. Supportive care remains the foundation, including blood pressure control, proteinuria reduction, kidney-protective medications, and lifestyle changes. But newer therapies now allow clinicians to target different parts of the disease process, from gut immune activity and endothelin signaling to complement activation and APRIL-driven antibody production.
For patients, this means more options, more personalized care, and more reason for optimism. It also means treatment decisions can be complex. The best plan depends on risk level, kidney function, proteinuria, biopsy findings, safety considerations, and personal goals. IgA nephropathy is still a serious disease, but the modern approach is no longer limited to waiting for decline. Today, the goal is to intervene earlier, monitor smarter, and protect kidney function for as long as possible.
Note: This article is for educational purposes only and should not replace medical advice. People with IgA nephropathy should work with a qualified nephrologist before starting, stopping, or changing any treatment.
